1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006; 5:64–74.
Article
2. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology. 1999; 52:1687–9.
Article
3. Zhang T, Shaw M, Cherbuin N. Association between type 2 diabetes mellitus and brain atrophy: a meta-analysis. Diabetes Metab J. 2022; 46:781–802.
Article
4. Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care. 2013; 36:4036–42.
5. Zhang W, Gao C, Qing Z, Zhang Z, Bi Y, Zeng W, et al. Hippocampal subfields atrophy contribute more to cognitive impairment in middle-aged patients with type 2 diabetes rather than microvascular lesions. Acta Diabetol. 2021; 58:1023–33.
Article
6. Zhou JB, Tang X, Han M, Yang J, Simo R. Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis. Metabolism. 2020; 109:154265.
Article
7. McIntosh EC, Nation DA; Alzheimer’s Disease Neuroimaging Initiative. Importance of treatment status in links between type 2 diabetes and Alzheimer’s disease. Diabetes Care. 2019; 42:972–9.
Article
8. Carmichael OT, Neiberg RH, Dutton GR, Hayden KM, Horton E, Pi-Sunyer FX, et al. Long-term change in physiological markers and cognitive performance in type 2 diabetes: the Look AHEAD Study. J Clin Endocrinol Metab. 2020; 105:e4778–91.
Article
9. Tang X, Cardoso MA, Yang J, Zhou JB, Simo R. Impact of intensive glucose control on brain health: meta-analysis of cumulative data from 16,584 patients with type 2 diabetes mellitus. Diabetes Ther. 2021; 12:765–79.
Article
10. Penaherrera-Oviedo C, Moreno-Zambrano D, Palacios M, Duarte-Martinez MC, Cevallos C, Gamboa X, et al. Does intensive glucose control prevent cognitive decline in diabetes?: a meta-analysis. Int J Chronic Dis. 2015; 2015:680104.